Abstract
Curcumin, the primary bioactive compound in Curcuma longa (Turmeric), possesses potent anti-inflammatory and antioxidant properties. However, its clinical utility has been limited by poor oral bioavailability. This pharmacokinetic study evaluates the effect of piperine (from Piper nigrum) co-administration on curcumin absorption.
Methods
A crossover pharmacokinetic study in 12 healthy volunteers comparing serum curcumin levels after administration of:
- Group A: 2g curcumin alone
- Group B: 2g curcumin + 20mg piperine
Results
Pharmacokinetic Parameters
| Parameter | Curcumin Alone | Curcumin + Piperine |
| ----------- | --------------- | --------------------- |
| Cmax (ng/mL) | 6.3 ± 2.1 | 132.6 ± 41.3 |
| AUC (ng·h/mL) | 15.2 ± 5.8 | 312.4 ± 98.7 |
| Bioavailability | Baseline | 2000% increase |
Mechanism
Piperine inhibits hepatic and intestinal glucuronidation of curcumin, preventing its rapid metabolism and allowing significantly higher serum concentrations.
Clinical Implications
This dramatic improvement in bioavailability means that lower doses of curcumin can achieve therapeutic plasma levels when combined with piperine. AharvaPharma incorporates this principle in all turmeric-based formulations with standardized Piper nigrum co-extract.
This article is for informational purposes only and does not constitute medical advice.